Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Arrowhead Portfolio Companies, Calando Pharmaceuticals, Inc. and Nanotope, Inc., Awarded Federal Grants to Advance Therapeutics

Abstract:
Arrowhead Research Corporation (ARWR 0.98, +0.01, +0.67%) today announced that its portfolio companies, Calando Pharmaceuticals, Inc. and Nanotope, Inc., have been awarded cash grants totaling $490,000 ($245,000 each) under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program.

Arrowhead Portfolio Companies, Calando Pharmaceuticals, Inc. and Nanotope, Inc., Awarded Federal Grants to Advance Therapeutics

Pasadena, CA | Posted on November 4th, 2010

Commenting on the awards, Dr. Christopher Anzalone, Arrowhead's President and Chief Executive Officer, stated, "The QTDP grants will help fund Calando's ongoing Phase I trial for CALAA-01, a leading siRNA therapeutic targeting cancer, and Nanotope's regenerative compounds that promote healing for spinal cord and other tissues. The approval process for the awards was very competitive and we are pleased that our therapeutic programs have been recognized."

Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics, developing nanoparticle therapeutics that use patented sugar (cyclodextrin) -based polymer technologies as a drug delivery system for siRNA. Engineered to reduce the debilitating effects of cancer treatment, Calando's proprietary molecules are designed to improve the safety and efficacy of cancer therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the potential to be applied to a wide range of diseases beyond cancer, as well as to therapeutic classes beyond siRNA therapeutics. CALAA-01, Calando's leading drug candidate, is a combination of Calando's delivery system and a patented siRNA targeting the M2 subunit of ribonucleotide reductase, a clinically-validated cancer target. Ribonucleotide reductase catalyzes the conversion of ribonucleosides to deoxyribonucleosides and is necessary for DNA synthesis and replication. It is a critical component in the proliferation of cancer cells. Calando's siRNA and CALAA-01 have demonstrated potent anti-proliferative activity across multiple types of cancer cells.

Nanotope is a regenerative medicine company that leverages a platform technology to address multiple therapeutic markets. It is developing a suite of products, each customized to regenerate specific tissues: including neuronal, vascular, cartilage, bone, and myocardial. Products are injectable compounds that work with surviving cells in and around the point of injury to initiate and support regeneration. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead candidates, shown to be effective in multiple animal models, target: (i) spinal cord regeneration for the reversal of paralysis; (ii) reversal of neuronal regeneration associated with Parkinson's disease; (iii) cartilage regeneration; and (iv) advanced wound healing. Nanotope entered into a partnership with Smith & Nephew in October 2010 to commercialize its cartilage regeneration.

The Qualifying Therapeutic Discovery Project program targeted therapeutic discovery projects that showed a reasonable potential to:

Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, Reduce the long-term growth of health care costs in the United States, or Significantly advance the goal of curing cancer within 30 years.

The program also took into consideration which projects showed the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the current state of the economy, capital resources available to us, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our most recent Annual Report on Form 10-K, as amended, and subsequent Quarterly Reports on Form 10-Q and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition, including the risks relating to the development of new drug candidates. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (ARWR 0.98, +0.01, +0.67%) is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and minority investments in two privately held nanobiotech companies.

For more information, please click here

Contacts:
The Piacente Group, Inc.
Brandi Floberg
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

SEFCU, SUNY Poly CNSE Announce Winning Student-Led Teams in the 6th Annual $500,000 New York Business Plan Competition April 25th, 2015

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

Nanomedicine

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Announcements

SEFCU, SUNY Poly CNSE Announce Winning Student-Led Teams in the 6th Annual $500,000 New York Business Plan Competition April 25th, 2015

Northwestern scientists develop first liquid nanolaser: Technology could lead to new way of doing 'lab on a chip' medical diagnostics April 25th, 2015

Nanotech-enabled moisturizer speeds healing of diabetic skin wounds: Spherical nucleic acids silence gene that interferes with wound healing April 24th, 2015

Fast and accurate 3-D imaging technique to track optically trapped particles April 24th, 2015

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

SEFCU, SUNY Poly CNSE Announce Winning Student-Led Teams in the 6th Annual $500,000 New York Business Plan Competition April 25th, 2015

Richards-Kortum elected to American Academy of Arts and Sciences: April 22nd, 2015

‘Oxford Instruments Young Nanoscientist India Award 2015’ to Prof. Arindam Ghosh April 20th, 2015

Iranian Female Professor Awarded UNESCO Medal in Nanoscience April 20th, 2015

Nanobiotechnology

A silver lining: UCSB researchers cradle silver nanoclusters inside synthetic DNA to create a programmed, tunable fluorescent array April 23rd, 2015

Scientists Use Nanoscale Building Blocks and DNA 'Glue' to Shape 3D Superlattices: New approach to designing ordered composite materials for possible energy applications April 23rd, 2015

UCLA nanoscientists are first to model atomic structures of three bacterial nanomachines: Cryo electron microscope enables scientists to explore the frontiers of targeted antibiotics April 21st, 2015

Rafts on the cell membrane: Researchers from TU Wien (Vienna) shed light on a big secret of cell membranes: The 'lipid rafts', which have been believed to move within the cell membrane, do not really exist April 21st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project